Overview
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
Status:
Completed
Completed
Trial end date:
2005-08-01
2005-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Chugai Pharmaceutical
Criteria
Inclusion criteria- Patients who are diagnosed with RA according to the 1987 American College of
Rheumatology (ACR) classification criteria
- Patients who contracted RA at least 6 months prior
Exclusion criteria
- Patients with Class IV Steinbrocker functional impairment at enrollment.
- Patients who have been treated for the underlying disease with a biological agent,
such as infliximab or etanercept and have been receiving treatment with leflunomide,
within 12 weeks before initiation of treatment with the probe drug